Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DDB1 | Q16531 | 1/20 | 0.50 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.40 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16369888 | 0.83 | ALDH1A1 (0.46) | DDB1CRBNALDH1A1 | |
| SCHEMBL28055381 | 0.76 | DDB1 (0.64) | DDB1CRBNALDH1A1KMT2ACYP3A4 | |
| SCHEMBL28055405 | 0.76 | DDB1 (0.64) | DDB1CRBNALDH1A1KMT2ACYP3A4 | |
| SCHEMBL7608143 | 0.74 | ALDH1A1 (0.49) | DDB1CRBNALDH1A1KMT2AMEN1 | |
| SCHEMBL7378336 | 0.72 | ALDH1A1 (0.46) | DDB1CRBNALDH1A1KMT2AMEN1 | |
| SCHEMBL5319955 | 0.71 | DDB1 (0.51) | DDB1CRBNALDH1A1 | |
| SCHEMBL2125064 | 0.71 | DDB1 (0.54) | DDB1CRBNALDH1A1 | |
| SCHEMBL18255040 | 0.70 | DDB1 (0.53) | DDB1CRBNALDH1A1KMT2ACYP3A4 | |
| SCHEMBL14537683 | 0.70 | DDB1 (0.50) | DDB1CRBNALDH1A1 | |
| SCHEMBL4962412 | 0.70 | DDB1 (0.56) | DDB1CRBNALDH1A1KMT2AMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160158200-A1 | Combinations of Hepatitis C Virus Inhibitors | BRISTOL MYERS SQUIBB CO (US) | 2016-06-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160158200-A1 | Combinations of Hepatitis C Virus Inhibitors | HAVCR2, EIF2AK2, MAVS | DDB1 279/4885CRBN 1931/4885ALDH1A1 3872/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.